SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04964024

Enrollment

1293

Registered

2021-07-15

Start date

2021-07-15

Completion date

2022-05-15

Last updated

2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Infection

Keywords

SARS-CoV-2, Antibodies, Vaccination, Nursing Homes

Brief summary

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease. Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Interventions

DIAGNOSTIC_TESTSARS-CoV-2 antibodies

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 110 Years

Healthy volunteers

Yes

Inclusion criteria

For Residents: * Living in one of the 9 Nursing Homes that participate in this study * Having a SARS-COV-2 post vaccination serology. * Having no objection for using the results of the serology for the purpose of this analysis For Health Professionals: * Working in one of the 9 Nursing Homes that participate in this study, * Having a SARS-COV-2 post vaccination serology. * Having no objection for using the results of the serology for the purpose of this analysis

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Levels of SARS-COV-2 antibodies	Through study completion average 6 months Retrospective analysis	Study of the SARS-COV-2 antibodies according to the history of COVID-19 and vaccinal status in Nursing Home residents and in health professionals

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026